Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

Completed · Phase 4

Conditions studied: Coronary Artery Disease

In brief

Early stent thrombosis has been noted with increased frequency in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) who are treated with bivalirudin and clopidogrel. The brief half life of bivalirudin acting in concert with the delayed action of clopidogrel likely exposes patients to thrombosis during a vulnerable period of reduced antiplatelet effect in the immediate post stenting period. Combination therapy with bivalirudin and prasugrel is conceptually attractive as the more rapid onset of action of prasugrel could potentially significantly diminish the vulnerable period, likely reducing the potential for acute stent thrombosis. The trials which have documented the efficacy of prasugrel as compared to clopidogrel have, in general, not reported on patients in whom bivalirudin was utilized. Currently, in the United States, bivalirudin is the most commonly used adjunctive agent used during PCI. Using light transmission aggregometry, this study will examine the inhibition of platelet aggregation in patients randomized to treatment with clopidogrel vs prasugrel during the vulnerable period following the discontinuation of bivalirudin therapy. The investigators anticipate that this study will document significant enhancement of inhibition of platelet aggregation in patients randomized to prasugrel treatment.

Key facts

Study ID

NCT01789814

Run by

Tufts Medical Center

People needed

24

Starts

2013-07-01

Expected to finish

2014-07-01

Last updated by the study team

2017-04-04

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent before initiation of any study related procedures
• Male or non-pregnant female aged 18 to ≤ 75 years
• Referred for PCI or structural cardiac intervention and planned to receive bivalirudin treatment
• Only subjects in whom the treating physician feels that clopidogrel and prasugrel are equivalent on the basis of available clinical literature will be included.

You may not qualify if…

• Currently receiving glycoprotein IIb/IIIa inhibitors.
• Have received prasugrel or clopidogrel within 2 weeks
• Serum creatinine level >2.0
• Hypersensitivity to bivalirudin, prasugrel, clopidogrel or aspirin
• Currently on heparin administration or administered ≤ 4.5 h prior to intervention
• Thrombocytopenia (<50,000/µL)
• Severe systemic hypertension defined as systolic blood pressure >180 mm Hg and/or diastolic blood pressure >110 mm Hg
• Body weight < 60 kg
• Cardiogenic shock
• Acute pericarditis
• Active internal bleeding
• History of bleeding diathesis within previous thirty days
• Any history of intracranial hemorrhage, Transient ischemic attack (TIA ) or stroke
• Arteriovenous malformations or aneurysms
• Major surgical procedures or severe physical trauma within last thirty days.
• Symptoms or findings suggestive of aortic dissection
• Pregnancy
• Participation in other clinical research studies involving the evaluation of investigational drugs or devices within 30 days of enrollment
• Incompetent subjects or subjects otherwise unable to provide informed consent
• Subjects in whom the treating physician believes that one agent (prasugrel or clopidogrel) is preferable over the other will be excluded from study participation.

Where it is running

• Tufts Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.